Ocugen, Inc. (OCGN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 2 | 6 | 4 | 4 | 5 | 5 |
| Operating profit | $m | -63 | -69 | ||||||
| Net profit | $m | -22 | -58 | -87 | -63 | -54 | -68 | -82 | -81 |
| EPS reported | $ | -0.23 | -0.25 | ||||||
| Operating cashflow per share | $ | -0.19 | -0.18 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.19 | -0.18 | ||||||
| Free cash flow | $m | -57 | -61 | ||||||
| Net debt | $m | 10 | -16 | ||||||
| Book value equity | $m | -12 | -17 | ||||||
| Book value per share | $ | -0.04 | -0.05 | ||||||
| Number of shares | m | 300.17 | 338.68 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -33.31 | -24.48 | ||||||
| P/S LTM | x | 91.83 | 88.48 | ||||||
| P/FCF LTM | x | -7.09 | -6.60 | ||||||
| EV/EBITDA LTM | x | -6.97 | -5.99 | ||||||
| EV/Sales LTM | x | 95.13 | 97.32 | ||||||
| Earnings Yield LTM | % | -16.74% | -17.89% | ||||||
| FCF Yield | % | -14.10% | -15.15% | ||||||
| Quality | |||||||||
| ROE | % | +557.67% | +1688.2% | ||||||
| ROIC | % | -2.79% | -92.68% | ||||||
| Operating margin | % | -14.26% | -15.04% | ||||||
| Gross margin | % | +45.86% | +100.00% | ||||||
| FCF/Sales | % | -1295.0% | -1340.1% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +8.83% | +12.95% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.72 | -0.70 | ||||||
| Net Debt/EBITDA | x | -0.24 | 0.17 | ||||||
| EBIT/Net interest | x | -12.13 | -8.16 | ||||||
| Net debt/market cap | % | +7.11% | +18.37% | ||||||
| Net debt/Equity | x | -0.84 | 0.96 | ||||||
| Gross debt/equity | x | -2.72 | -5.31 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free